Japanese Multicenter Outcomes With the HeartMate II Left Ventricular Assist Device in Patients With Small Body Surface Area
|
|
- Kelly Paul
- 6 years ago
- Views:
Transcription
1 Circulation Journal Official Journal of the Japanese Circulation Society Advance Publication by-j-stage Japanese Multicenter Outcomes With the HeartMate II Left Ventricular Assist Device in Patients With Small Body Surface Area Minoru Ono, MD, PhD; Yoshiki Sawa, MD, PhD; Takeshi Nakatani, MD, PhD; Ryuji Tominaga, MD, PhD; Yoshiro Matsui, MD, PhD; Kenji Yamazaki, MD, PhD; Yoshikatsu Saiki, MD, PhD; Hiroshi Niinami, MD, PhD; Goro Matsumiya, MD, PhD; Hirokuni Arai, MD, PhD on behalf of Japanese HeartMate II investigators Background: The HeartMate II (HMII) continuous-flow LVAD was approved for Japanese health insurance coverage in April 2013 as a bridge to transplantation (BTT). We report on post-approval Japanese multicenter outcomes, and a comparison between patients with low and high body surface area (BSA). Methods and Results: HMII LVAD was implanted in 104 consecutive patients at 15 Japanese centers between April 2013 and July Perioperative data were submitted to the Japanese Registry for Mechanically Assisted Circulatory Support. Patients were divided into 2 groups on the basis of BSA less or greater than 1.5 m 2. Survival outcomes, New York Heart Association functional class, and adverse event rates were compared between the 2 groups. Preoperative hemodynamics and INTERMACS profiles were similar between groups. There were more females and younger patients in the low BSA group. The respective 6-month and 1-year death- or pump exchangefree survival rates were excellent: 90% and 90% in the BSA <1.5 group vs. 90% and 85% in the BSA 1.5 group. In the BSA <1.5 group, occurrence of hemorrhagic stroke was 10% and occurrence of embolic stroke was 0%, vs. 12% and 8% in BSA 1.5 group. Driveline infection was encountered more frequently in the BSA <1.5 group. Conclusions: Results for HMII LVAD as BTT in the post-approval era showed excellent survival and functional capacity improvement. Of particular interest to the Japanese patient population are the excellent results in patients with small BSA. Key Words: Heart failure; Multicenter registry; Ventricular assist device Implantable left ventricular assist devices (LVADs) are an important treatment option for the growing worldwide population of patients with advanced heart failure. Implanting, and then safely supporting the circulation of patients with devices containing electric motors, pumping mechanisms, and conduits attached to the heart and major blood vessels, is not trivial. The 1st-generation implantable pulsatile LVADs were designed to mimic the natural heart by providing a stroke volume and pump rate that could generate a cardiac output up to 10 L/min; accordingly, these devices were large and could only be accommodated by patients with a body surface area (BSA) >1.5 m 2. Children and adult populations with a smaller BSA were disadvantaged by the size of these LVADs and were usually excluded as candidates for implantation. The introduction of the smaller continuous-flow LVAD offered the prospect of treating a broader range of patient size, to a BSA as small as 1.3 m 2. The HeartMate II (HMII) LVAD (Thoratec Corp, Pleasanton, CA, USA) has been implanted in Received March 24, 2016; revised manuscript received June 3, 2016; accepted June 6, 2016; released online July 4, 2016 Time for primary review: 33 days Department of Cardiac Surgery, The University of Tokyo, Tokyo (M.O.); Department of Cardiovascular Surgery, Osaka University, Osaka (Y. Sawa); Department of Transplantation, National Cardiovascular Research Center, Osaka (T.N.); Department of Cardiovascular Surgery, Kyushu University, Fukuoka (R.T.); Department of Cardiovascular Surgery, Hokkaido University, Sapporo (Y.M.); Department of Cardiovascular Surgery, Tokyo Women s Medical University, Tokyo (K.Y.); Department of Cardiovascular Surgery, Tohoku University, Sendai (Y. Saiki); Department of Cardiovascular Surgery, Saitama Medical University, Hidaka (H.N.); Department of Cardiovascular Surgery, Chiba University, Chiba (G.M.); and Department of Cardiovascular Surgery, Tokyo Medical and Dental University, Tokyo (H.A.), Japan This paper was presented at the 35 th annual meeting of the International Society for Heart and Lung Transplantation, April 2015, Nice, France. Mailing address: Minoru Ono, MD, PhD, Department of Cardiac Surgery, The University of Tokyo, Hongo, Bunkyo-ku, Tokyo , Japan. ono-tho@h.u-tokyo.ac.jp ISSN doi: /circj.CJ All rights are reserved to the Japanese Circulation Society. For permissions, please cj@j-circ.or.jp
2 Advance Publication by-j-stage ONO M et al. Figure 1. Trend in PT-INR among Japanese recipients of the HeartMate II left ventricular assist device. BSA, body surface area; PT-INR, prothrombin time-international normalized ratio. more than 20,000 patients worldwide, with the majority being adults with an average BSA of 2.0 m Experience with implanting durable LVADs in patients with a BSA <1.5 m 2 is limited mostly to the pediatric population. Paracorporeal pneumatically powered pulsatile ventricular assist devices (VADs) have been most commonly used in small BSA patients; however, restricted mobility and higher complication rates lead to less favorable outcomes when compared with larger patients supported by continuous-flow LVADs. 4 9 To date, the largest clinical experience with the HMII has been in the USA and Europe, where the average BSA is larger than in the Japanese population. With the increased use of this device in Japan as a bridge to transplant (BTT), there is now greater experience with implantation in patients with a BSA <1.5 m 2. This study was conducted to assess any differences in outcomes and adverse events (AE) in patients within the range of smaller BSA. Methods Patients This study was a retrospective analysis of patients implanted with the HMII LVAD as BTT therapy at 15 institutions in Japan. The data presented represents follow-up data in all patients who underwent HMII implantation between April 2013 and July The inclusion and exclusion criteria for implantation of the HMII LVAD have been previously published. 10 Before LVAD implantation, all patients provided informed consent. All data used in this analysis were obtained from the Japanese Registry for Mechanically Assisted Circulatory Support (J-MACS). Patients were divided into 2 groups based on a pre-lvad implant BSA <1.5 m 2 (n=30) or 1.5 m 2 (n=74). Baseline characteristics, duration of LVAD support, clinical outcomes, survival, and AEs were compared between the 2 groups. Any cases of malposition of the device or issues related to the size of the device or the patient were examined. Data regarding pump speed and estimated flow rate was compared between groups. Device Implantation The HMII LVAD was implanted by median sternotomy in all patients except in 5 cases in which pump exchange from another type of VAD was performed via subcostal incision. Standard cardiopulmonary bypass was established by aortic perfusion with bicaval or single atrial drainage, according to whether the patient required additional procedures or to follow each institutional policy. The majority of implants were performed under beating-heart conditions. Before starting cardiopulmonary bypass, a pump pocket was created in the left subcostal area. The pump pocket was created inferior and laterally enough to place the pump with an ideal inflow angle in small BSA patients. The pump pocket was further extended toward the right beyond the midline in some patients with a small rib cage or short body width in order to lay the pump to avoid compression of the right ventricle. Heparin bridging in transition to warfarin after LVAD Table 1. Demographics of Japanese Recipients of the HeartMate II LVAD BSA <1.5 m 2 BSA 1.5 m 2 (n=30) (n=74) P value Age 38.5± ± Male (%) <0.001 BSA (m 2 ) 1.41± ±0.78 <0.001 BSA range (m 2 ) Etiology: ischemic (%) Systolic blood pressure (mmhg) 87.5± ± Prior LVAD (%) Inotropic support (%) Indexed cardiac output (L min 1 m 2 ) 2.16± ± LVEDD (mm) 59.9± ±13.7 <0.001 INTERMACS profile (%) 0.08 I II III IV V BSA, body surface area; INTERMACS, Interagency Registry for Mechanically Assisted Circulatory Support; LVAD, left ventricular assist device.
3 HM II LVAD in Small BSA Patients Advance Publication by-j-stage Table 2. Outcomes of Japanese HeartMate II Recipients (as of October 2014) BSA <1.5 m 2 (n=30) BSA 1.5 m 2 (n=74) n % n % P value Outcome 0.93 Ongoing support Transplanted Weaned Pump exchange Died on device Support duration (days) 347±178 (36 553) 296±185 (8 551) 0.12 Patient status at 6 months (n=22) (n=35) Systolic blood pressure (mmhg) 84.8± ± Estimated pump flow (L/min) 4.6± ± Pump speed (rpm) 8,524±4,166 8,657±4, Figure 2. Freedom from all causes of death among Japanese recipients of the HeartMate II left ventricular assist device. BSA, body surface area. implantation was not routinely implemented. Anticoagulation management included warfarin, with a target prothrombin timeinternational normalized ratio (PT-INR) range of and 100 mg of aspirin (Figure 1). Platelet function tests, such as thromboelastography, were not routinely used. Statistical Analysis Differences in categorical variables between groups were evaluated using the t-test and the Chi-square test, as appropriate. Statistical comparisons were 2-sided, and significance was set as P<0.05. Survival analysis was performed using the Kaplan-Meier method, with censoring for ongoing device support, transplantation, and recovery of heart function with device explant. Comparison of survival rates between the 2 groups was performed using the log-rank test. AEs are presented as percentage of patients and event rates (events per patient-year (EPPY)). All statistical analyses were done using JMP 11.0 (SAS Institute, Cary, NC, USA). Results The 104 patients implanted with the HMII LVAD between April 2013 and July 2014 were included in the analysis. There were 30 patients in BSA <1.5 group and 74 patients in BSA 1.5 group. The baseline characteristics of the 2 study groups are provided in Table 1. Patients in the BSA <1.5 group were younger (mean age 38.5±15.4 vs. 45.3±12.7; P=0.04) and there was a larger proportion of females (53.4% vs. 13.5%; P<0.001) than in the BSA 1.5 group. The mean BSA for each group was 1.41±0.07 and 1.69±0.11, respectively (P<0.0001). Ischemic heart disease was present in 12 (16.2%) of the BSA 1.5 m 2 group compared with none in the BSA 1.5 group (P=0.017). In the BSA <1.5 m 2 group, there were 13 patients (43.3%) who had been supported by another type of VAD (Nipro paracorporeal pneumatically driven VAD (Nipro, Osaka, Japan)), which was significantly more frequent than the BSA 1.5 m 2 group (18.9%, P=0.02). Left ventricular end-diastolic dimension before LVAD implantation was significantly smaller in the BSA <1.5 m 2 group (P<0.001).
4 Advance Publication by-j-stage ONO M et al. group and 5 in the BSA 1.5 m 2 group (Table 2). The causes of death were a cerebrovascular event and infection in the BSA <1.5 m 2 group and all were cerebrovascular events in the BSA 1.5 m 2 group. The Kaplan-Meier survival rate at 1 year was 92.6% and 90.9% (P=NS) for the BSA <1.5 m 2 and BSA 1.5 m 2 groups, respectively (Figure 2). If the patients were limited to those who underwent primary HMII implantation without prior paracorporeal VAD, 1 year survival rate was 93.8% and 92.5%, respectively (P=NS). The New York Heart Association (NYHA) functional class had improved dramatically at 6 months in both groups (Figure 3). As of October 2014, 28 of 30 (93.3%) patients in the BSA <1.5 m 2 group and 70 of 74 (94.5%) in the BSA 1.5 m 2 group had continued on LVAD support. Figure 3. Trend in New York Heart Association functional class among Japanese recipients of the HeartMate II left ventricular assist device. BSA, body surface area. Initial pump speed was set at 8,200 8,600 rpm in the majority of patients with small BSA, and appropriate pump speed was adjusted before discharge and at the time of outpatient clinic visit according to echocardiographic measurement or estimated flow on the monitor. During support, the average pump speed at 6 months was 8,524 rpm in the small BSA group, which was slower than that of the larger BSA group (8,657 rpm), but not statistically significant (P=0.08). Estimated pump flow rate at 6 months was similar in both groups (Table 2). The average support duration of support for the BSA <1.5 m 2 group and BSA 1.5 m 2 group was 347±178 days and 296±185 days, respectively. The cumulative duration of support was 28.5 years for the BSA <1.5 m 2 group and 60.0 years for BSA 1.5 m 2 group. One patient in each group underwent heart transplantation. There were 7 deaths: 2 in the BSA <1.5 m 2 Adverse Events Driveline infection was the most frequent AE and was significantly higher in the group with BSA <1.5 m 2 (Table 3). Embolic stroke occurred more frequently in the BSA 1.5 m 2 group (P=0.001), whereas hemorrhagic stroke was nearly equal in both groups. Ventricular arrhythmia that required electrical or pharmacological conversion was documented more frequently in the BSA 1.5 m 2 group (P=0.001). There was a trend toward a higher rate of occurrence of right heart failure in the BSA <1.5 m 2 group, but was not significant. Pump thrombosis occurred similarly in both groups, with respective rates of 0.08 and 0.07 EPPY. During the 1-year follow-up period, there were no differences in hematologic or biochemistry laboratory values (Table S1). The trend in lactate dehydrogenase (LDH) levels was the same in both groups (Figure 4). There were 6 pump exchanges, 2 of which were performed in 1 patient in the BSA <1.5 group for pump thrombosis, and 4 in the BSA 1.5 group (3 for pump thrombosis, 1 for pump pocket infection). Another type of VAD was used in 1 of 4 pump exchanges in the BSA >1.5 group. Death or pump exchange-free survival at 1 year was 90% in the BSA <1.5 group and 85% in the BSA 1.5 group (P=NS; Figure 5). If the patients were limited to those who underwent primary HMII implantation, the death or pump exchange-free survival was 88.2% and 88.3%, respectively (P=NS). Table 3. Adverse Event Rates Among Japanese Recipients of the HeartMate II LVAD BSA <1.5 m 2 (n=30) EPPY BSA 1.5 m 2 (n=74) EPPY P value Infection Driveline Pump pocket 0 0 Pump 0 0 Mediastinum NS Cerebrovascular event Embolic Hemorrhagic NS Other events Gastrointestinal bleeding NS Ventricular arrhythmia Right heart failure Myocardial infarction NS Pump thrombosis NS EPPY, events per patient-year; NS, not significant; VAD, ventricular assist device.
5 HM II LVAD in Small BSA Patients Advance Publication by-j-stage Discussion The use of continuous-flow LVADs for supporting patients with endstage heart failure has increased greatly in recent years because of the improved outcomes and better acceptance of the technology. 1 3,10 12 The smaller LVAD can be implanted with less surgical trauma, shorter cardiopulmonary bypass time, shorter recovery time, and overall fewer AEs related to implantation. 13,14 The smaller devices should allow implantation in a much larger population of heart failure patients, such as children and small adults. This study indicates that the HMII can safely and effectively support the Japanese population of adults with heart failure and lower BSA. Data from INTERMACS in the USA show that the average size of patients implanted with the earlier generation of pulsatile devices was 2.27 m 2, and now those implanted with the current continuous-flow LVAD have an average BSA of 2.04 m To date, experience with HMII implantation in patients with a BSA <1.5 m 2 has been limited. The HMII trials for both BTT and destination therapy (DT) had a lower limit of BSA at 1.3 m 2, but these trials also limited enrollment to patients older than 18 years of age, which excluded smaller, younger children. However, the US clinical trial did have a cohort of small BSA <1.5 m 2 patients, with results that were equivalent to the study as a whole. 16,17 Even in the post-trial studies with fewer restrictions on patient selection, the average size of patients did not decline. 2,3 In a recent study of pediatric and young adult patients implanted with the HMII LVAD, the average BSA was 1.91 m 2 ( m 2 ) and 2.08 m 2 ( m 2 ) in the 2 cohorts, which is still not representative of a small-size population. 18 This is one of the first published reports of HMII LVAD use in a population of patients with a BSA <1.5 m 2. There has been discussion about possible increased risk of pump thrombosis in cases of lower pump speed and flow. In this multicenter study, we carefully checked the pump speed at 6 months; speeds were 8,524±4,166 rpm in the BSA <1.5 m 2 group and 8,657±4,238 rpm in the BSA 1.5 m 2 group. PT- INR levels were strictly controlled between 2.0 and 2.5, as Figure 4. Trend in lactate dehydrogenase (LDH) among Japanese recipients of the HeartMate II left ventricular assist device. BSA, body surface area. shown in Figure 1. Pump thrombosis rates were lower than those reported in some studies from the USA. Thus, we believe the HMII LVAD can be implanted and managed safely in patients with small body size when PT-INR is strictly controlled. Higher pump speed, such as 9,400 rpm, is usually recommended in the US patient population to avoid pump thrombosis. In our experience, when the pump speed was increased as high as 9,400 rpm in a small patient, the interventricular septum was easily shifted toward the left ventricle and the chance of sucking events increased. We judged an optimal flow by observing the end-diastolic left ventricular dimension on echocardiography, by which means a sufficient assist flow was obtained while preserving a safe lv dimension. The implant centers exchanged ideas on how to safely and effectively create a pump pocket in a patient with small body size. This exchange of ideas may have contributed to a uniform pump pocket creation technique and a lower pump Figure 5. Freedom from death or pump exchange among Japanese recipients of the HeartMate II left ventricular assist device. BSA, body surface area.
6 Advance Publication by-j-stage ONO M et al. thrombosis rate in the BSA <1.5 m 2 group despite the smaller LV. An interesting finding of this study was that very few gastrointestinal bleeding events occurred. However, our patients were younger than the DT patients in the USA, which may be an important factor. As already described, there was no significant difference in anticoagulation and antiplatelet therapies in Japan relative to that used in the USA. Whether the reduced occurrence of gastrointestinal bleeding is the result of any difference in intestinal arteriovenous fistula formation or stems from other genetic characteristics is to be elucidated. Conclusions Post-approval use of the HMII for BTT in Japan demonstrated excellent survival with improvement in functional capacity in the whole population. Of particular interest is that patients with a smaller BSA have equivalent outcomes and similar management to patients with a larger BSA. Disclosures None of the authors has a conflict of interest to disclose. The authors acknowledge all participants of the J-MACS Registry and all clinical institutions, surgeons and medical staff who contributed to this project. References 1. Starling RC, Naka Y, Boyle AJ, Gonzalez-Stawinski G, John R, Jorde U, et al. Results of the post-u.s. Food and Drug Administration-approval study with a continuous flow left ventricular assist device as a bridge to heart transplantation: A prospective study using the INTERMACS (Interagency Registry for Mechanically Assisted Circulatory Support). J Am Coll Cardiol 2011; 57: John R, Naka Y, Smedira NG, Starling R, Jorde U, Eckman P, et al. Continuous flow left ventricular assist device outcomes in commercial use compared with the prior clinical trial. Ann Thorac Surg 2011; 92: Jorde UP, Kushwaha SS, Tatooles AJ, Naka Y, Bhat G, Long JW, et al. Results of the destination therapy post-food and Drug Administration approval study with a continuous flow left ventricular assist device: A prospective study using the INTERMACS registry (Interagency Registry for Mechanically Assisted Circulatory Support). J Am Coll Cardiol 2014; 63: Hill JD, Reinhartz O. Clinical outcomes in pediatric patients implanted with Thoratec ventricular assist device. Semin Thorac Cardiovasc Surg Pediatr Card Surg Annu 2006: Fraser CD Jr, Jaquiss RD. The Berlin Heart EXCOR Pediatric ventricular assist device: History, North American experience, and future directions. Ann NY Acad Sci 2013; 1291: Fraser CD Jr, Jaquiss RD, Rosenthal DN, Humpl T, Canter CE, Blackstone EH, et al. Prospective trial of a pediatric ventricular assist device. N Engl J Med 2012; 367: Sandica E, Knyphausen EZ, Blanz U, Rofe D, Morshuis M. Safety of long-term mechanical support with Berlin Heart EXCOR in pediatric patients. World J Pediatr Congenit Heart Surg 2012; 3: Hetzer R, Potapov EV, Stiller B, Weng Y, Hübler M, Lemmer J, et al. Improvement in survival after mechanical circulatory support with pneumatic pulsatile ventricular assist devices in pediatric patients. Ann Thorac Surg 2006; 82: Almond CS, Morales DL, Blackstone EH, Turrentine MW, Imamura M, Massicotte MP, et al. Berlin Heart EXCOR pediatric ventricular assist device for bridge to heart transplantation in US children. Circulation 2013; 127: Kyo S, Ono M, Sawa Y, Nakatani T, Tabayashi K, Saiki Y, et al. Results of the prospective multicenter Japanese bridge to transplant study with a continuous-flow left ventricular assist device. J Artif Organs 2014; 17: Imamura T, Kinugawa K, Nitta D, Hatano M, Kinoshita O, Nawata K, et al. Perioperative hypoalbuminemia affects improvement in exercise tolerance after left ventricular assist device implantation. Circ J 2015; 79: Kimura M, Kinoshita O, Nawata K, Nishimura T, Hatano M, Imamura T, et al. Midterm outcome of implantable left ventricular assist devices as a bridge to transplantation: Single-center experience in Japan. J Cardiol 2015; 65: John R, Kamdar F, Liao K, Colvin-Adams M, Boyle A, Joyce L. Improved survival and decreasing incidence of adverse events with the HeartMate II left ventricular assist device as bridge-to-transplant therapy. Ann Thorac Surg 2008; 86: Gafoor S, Franke J, Lam S, Reinartz M, Bertog S, Vaskelyte L, et al. Devices in heart failure: The new revolution. Circ J 2015; 79: Kirklin JK, Naftel DC, Pagani FD, Kormos RL, Stevenson L, Miller M, et al. Long-term mechanical circulatory support (destination therapy): On track to compete with heart transplantation? J Thorac Cardiovasc Surg 2012; 144: Thoratec Corporation. HeartMate II left ventricular assist system: Instructions for use. May Lee S, Katz JN, Pagani FD, Jorde UP, Moazami N, John R, et al. Outcomes of adult patients with small body size supported with a continuous-flow left ventricular assist device. J Heart Lung Transplant 2014; 33: S102 S Cabrera AG, Sundareswaran KS, Samayoa AX, Jeewa A, McKenzie ED, Rossano JW, et al. Outcomes of pediatric patients supported by the HeartMate II left ventricular assist device in the United States. J Heart Lung Transplant 2013; 32: Supplementary Files Supplementary File 1 Table S1. Laboratory values before implantation of the HeartMate II LVAD, and at 6 and 12 months after Please find supplementary file(s);
Japanese Multicenter Outcomes With the HeartMate II Left Ventricular Assist Device in Patients With Small Body Surface Area
Circulation Journal Official Journal of the Japanese Circulation Society http://www.j-circ.or.jp ORIGINAL ARTICLE Cardiovascular Surgery Japanese Multicenter Outcomes With the HeartMate II Left Ventricular
More informationHEARTMATE II LEFT VENTRICULAR ASSIST SYSTEM. HeartMate II Left Ventricular Assist Device
HEARTMATE II LEFT VENTRICULAR ASSIST SYSTEM HeartMate II Left Ventricular Assist Device HeartMate II Left Ventricular Assist Device UNPARALLELED REAL-WORLD EXPERIENCE Over 25,000 heart failure patients
More informationRisk Factors for Adverse Outcome after HeartMate II Jennifer Cowger, MD, MS St. Vincent Heart Center of Indiana
Risk Factors for Adverse Outcome after HeartMate II Jennifer Cowger, MD, MS St. Vincent Heart Center of Indiana Advanced Heart Failure, Transplant, & Mechanical Circulatory Support Relevant Financial Relationship
More informationMechanical Circulatory Support in the Management of Heart Failure
Mechanical Circulatory Support in the Management of Heart Failure Feras Bader, MD, MS, FACC Associate Professor of Medicine Director, Heart Failure and Transplant Cleveland Clinic Abu Dhabi Chairman, Heart
More informationLVAD Complications, Recovery
LVAD Complications, Recovery Abbas Ardehali, M.D., F.A.C.S. Professor of Surgery and Medicine, Division of Cardiac Surgery William E. Connor Chair in Cardiothoracic Transplantation Director, UCLA Heart,
More informationMCSD Pump Thrombosis : Industry Perspective
MCSD Pump Thrombosis : Industry Perspective John B. O Connell MD Vice President, Medical Affairs Thoratec Corporation 1 1 Thoratec Asia Pacific Mechanical Circulatory Support (MCS) Conference Agenda 15-17
More informationAnalysis of Pump Thrombosis in the Intermacs Database
Analysis of Pump Thrombosis in the Intermacs Database Michael Acker William Measey Professor of Surgery Chief of Division of Cardiovascular Surgery Director of Heart and Vascular Center University of Pennsylvania
More informationFifth INTERMACS annual report: Risk factor analysis from more than 6,000 mechanical circulatory support patients
http://www.jhltonline.org SPECIAL FEATURE Fifth INTERMACS annual report: Risk factor analysis from more than 6, mechanical circulatory support patients James K. Kirklin, MD, a David C. Naftel, PhD, a Robert
More informationEvaluation of Native Left Ventricular Function During Mechanical Circulatory Support.: Theoretical Basis and Clinical Limitations
Review Evaluation of Native Left Ventricular Function During Mechanical Circulatory Support.: Theoretical Basis and Clinical Limitations Tohru Sakamoto, MD, PhD Left ventricular function on patients with
More informationLeft Ventricular Assist Devices (LVADs): Overview and Future Directions
Left Ventricular Assist Devices (LVADs): Overview and Future Directions FATIMA KARAKI, M.D. PGY-3, DEPARTMENT OF MEDICINE WASHINGTON UNIVERSITY IN ST. LOUIS ST. LOUIS, MISSOURI, USA St. Louis, Missouri,
More informationVentricular Assist Devices for Permanent Therapy: Current Status and Future
Ventricular Assist Devices for Permanent Therapy: Current Status and Future Prospects Francis D. Pagani MD PhD Professor of Cardiac Surgery University of Michigan April 28 th, 2012 Disclosures NHLBI and
More informationIs it time to consider a HEARTMATE LEFT VENTRICULAR ASSIST DEVICE (LVAD)?
Is it time to consider a HEARTMATE LEFT VENTRICULAR ASSIST DEVICE (LVAD)? A treatment for advanced heart failure. LAURA HeartMate II LVAD Recipient What is HEART FAILURE? Heart failure sometimes called
More informationThe Japanese Organ Transplant Act came into effect
298 FUKUSHIMA N et al. Circ J 2017; 81: 298 303 doi: 10.1253/circj.CJ-16-0976 REPORT OF HEART TRANSPLANTATION IN JAPAN Registry Report on Heart Transplantation in Japan (June 2016) Norihide Fukushima,
More informationConcomitant Aortic Valve Procedures in Patients Undergoing Implantation of Continuous-Flow LVADs: An INTERMACS Database Analysis
Concomitant Aortic Valve Procedures in Patients Undergoing Implantation of Continuous-Flow LVADs: An INTERMACS Database Analysis April 11, 2014 Jason O. Robertson, M.D., M.S.; David C. Naftel, Ph.D., Sunil
More informationComplications of Left Ventricular Assist Device Chronic Support. Dr. Tal Hasin RMC, Beilinson, Petach-Tiqva, Israel
Complications of Left Ventricular Assist Device Chronic Support. Dr. Tal Hasin RMC, Beilinson, Petach-Tiqva, Israel No disclosures Probability of survival Survival (%) Survival with LVAD Destination Bridge
More informationHeartWare ADVANCE Bridge to Transplant Trial and Continued Access Protocol Update
HeartWare ADVANCE Bridge to Transplant Trial and Continued Access Protocol Update Mark S. Slaughter, MD University of Louisville, KY, USA HeartWare Users Meeting 29 October 2012 Barcelona, Spain HEARTWARE,
More informationHEARTMATE 3 LVAD WITH FULL MAGLEV FLOW TECHNOLOGY THEIR FUTURE STARTS WITH YOU
HEARTMATE 3 WITH FULL MAGLEV FLOW TECHNOLOGY THEIR FUTURE STARTS WITH YOU HEARTMATE 3 with Full MagLev Flow Technology HEARTMATE 3 DELIVERS UNPRECEDENTED * SURVIVAL AND SAFETY OUTCOMES **1 LANDMARK SURVIVAL
More informationA Fully Magnetically Levitated Left Ventricular Assist Device. Final Report of the MOMENTUM 3 Trial
A Fully Magnetically Levitated Left Ventricular Assist Device Final Report of the MOMENTUM 3 Trial Mandeep R. Mehra, MD, Nir Uriel, MD, Joseph C. Cleveland, Jr., MD, Daniel J. Goldstein, MD, National Principal
More informationORIGINAL ARTICLE. Alexander M. Bernhardt a, *, Theo M.M.H. De By b, Hermann Reichenspurner a and Tobias Deuse a. Abstract INTRODUCTION
European Journal of Cardio-Thoracic Surgery 48 (2015) 158 162 doi:10.1093/ejcts/ezu406 Advance Access publication 29 October 2014 ORIGINAL ARTICLE Cite this article as: Bernhardt AM, De By TMMH, Reichenspurner
More informationLessons learned from ENDURANCE, ROADMAP, MedaMACS, and how to go forward?
Lessons learned from ENDURANCE, ROADMAP, MedaMACS, and how to go forward? Mark S. Slaughter, MD Professor and Chair Department of Cardiovascular and Thoracic Surgery University of Louisville What could
More informationOutpatient Treatment of MCS Patient. F. Bennett Pearce, MD Professor of Pediatrics Med Director Heart Transplant COA
Outpatient Treatment of MCS Patient F. Bennett Pearce, MD Professor of Pediatrics Med Director Heart Transplant COA Disclosure Statement I DO NOT HAVE ANY RELEVANT FINANCIAL RELATIONSHIPS WITH ANY COMMERCIAL
More informationEMS: Care of the VAD Patient. Brittany Butzler BSN RN VAD Coordinator Froedtert and the Medical College of WI
EMS: Care of the VAD Patient Brittany Butzler BSN RN VAD Coordinator Froedtert and the Medical College of WI Disclosure No relevant financial relationships by planners or presenters Left Ventricular Assist
More informationLIVING A MORE ACTIVE LIFE. with the HeartMate 3 LVAD for the treatment of advanced heart failure RON. Recipient
LIVING A MORE ACTIVE LIFE with the HeartMate 3 LVAD for the treatment of advanced heart failure RON HeartMate 3 LVAD Recipient What is HEART FAILURE? Heart failure sometimes called a weak heart occurs
More informationRamani GV et al. Mayo Clin Proc 2010;85:180-95
THERAPIES FOR ADVANCED HEART FAILURE: WHEN TO REFER Navin Rajagopalan, MD Assistant Professor of Medicine University of Kentucky Director, Congestive Heart Failure Medical Director of Cardiac Transplantation
More informationMEDICAL POLICY SUBJECT: VENTRICULAR ASSIST DEVICES
MEDICAL POLICY PAGE: 1 OF: 7 If the member's subscriber contract excludes coverage for a specific service it is not covered under that contract. In such cases, medical policy criteria are not applied.
More informationContinuous Flow Left Ventricular Assist Device Outcomes in Commercial Use Compared With the Prior Clinical Trial
Continuous Flow Left Ventricular Assist Device Outcomes in Commercial Use Compared With the Prior Clinical Trial Ranjit John, MD, Yoshifumi Naka, MD, Nicholas G. Smedira, MD, Randall Starling, MD, MPH,
More informationHEARTMATE 3 LEFT VENTRICULAR ASSIST SYSTEM
HEARTMATE 3 LEFT VENTRICULAR ASSIST SYSTEM A New Milestone in LVAD Therapy HeartMate 3 Left Ventricular Assist Device Introducing the new HEARTMATE 3 LVAD WITH FULL MAGLEV FLOW TECHNOLOGY HeartMate 3 LVAD
More informationLEFT VENTRICULAR ASSIST DEVICE COMPLICATIONS. Daniel Vargas, MD Section of Cardiothoracic Imaging University of Colorado Anschutz Medical Campus
LEFT VENTRICULAR ASSIST DEVICE COMPLICATIONS Daniel Vargas, MD Section of Cardiothoracic Imaging University of Colorado Anschutz Medical Campus OBJECTIVES Review the most common LVAD-related complications.
More informationFurther devices to treat heart failure
Postgraduate Course Heart Failure Further devices to treat heart failure Pr. Matthias Kirsch Department of Cardiac Surgery Centre Hospitalo-Universitaire Vaudois Université de Lausanne e-mail: matthias.kirsch@chuv.ch
More informationThe Gold Standard in Pediatric VAD Therapy A Compilation of Publications Demonstrating the Clinical Excellence of EXCOR Pediatric
EXCOR Pediatric The Gold Standard in Pediatric VAD Therapy A Compilation of Publications Demonstrating the Clinical Excellence of EXCOR Pediatric EXCOR Pediatric The Gold Standard in Pediatric VAD Therapy
More informationFirst Experiences With the HeartWare Ventricular Assist System in Children
First Experiences With the HeartWare Ventricular Assist System in Children Oliver Miera, MD, Evgenij V. Potapov, MD, PhD, Matthias Redlin, MD, Alexander Stepanenko, MD, Felix Berger, MD, PhD, Roland Hetzer,
More informationMulticenter Study of MagLev Technology in Patients Undergoing Mechanical Circulatory Support Therapy with HeartMate 3 (MOMENTUM 3) Long Term Outcomes
Multicenter Study of MagLev Technology in Patients Undergoing Mechanical Circulatory Support Therapy with (MOMENTUM 3) Long Term Outcomes Mandeep R. Mehra, MD, Daniel J. Goldstein, MD, Nir Uriel, MD, Joseph
More informationStatus of Implantable VADs
Status of Implantable VADs John V. Conte, MD, Professor of Surgery Johns Hopkins University School of Medicine Division of Cardiac Surgery The Johns Hopkins Medical Institutions Conflict of Interest Statement
More informationNew ventricular assist devices. FW Mohr Clinical seminar: Devices for severe heart failure ESC congress Stockholm 2010
New ventricular assist devices FW Mohr Clinical seminar: Devices for severe heart failure ESC congress Stockholm 2010 The real world of CHF Prevalence 1-3% in europe, in the age of 70-80 years up to 10-20%
More informationMechanical Support in the Failing Fontan-Kreutzer
Mechanical Support in the Failing Fontan-Kreutzer Stephanie Fuller MD, MS Thomas L. Spray Endowed Chair in Congenital Heart Surgery Associate Professor, The Perelman School of Medicine at the University
More informationECMO as a Bridge to Heart Transplant in the Era of LVAD s.
Christian Bermudez MD. Associate Professor Director Thoracic Transplantation Division Cardiac Surgery Department of Surgery University of Pennsylvania ECMO as a Bridge to Heart Transplant in the Era of
More informationJournal of the American College of Cardiology Vol. 60, No. 1, by the American College of Cardiology Foundation ISSN /$36.
Journal of the American College of Cardiology Vol. 60, No. 1, 2012 2012 by the American College of Cardiology Foundation ISSN 0735-1097/$36.00 Published by Elsevier Inc. http://dx.doi.org/10.1016/j.jacc.2012.02.031
More informationVAD come Destination therapy nell adulto con Scompenso Cardiaco
VAD come Destination therapy nell adulto con Scompenso Cardiaco Francesco Santini Division of Cardiac Surgery, IRCCS San Martino IST University of Genova Medical School, Italy Heart Transplantation is
More informationWhat has INTERMACS Taught Us about Patient Outcomes with Durable MCS? James K. Kirklin, MD
What has INTERMACS Taught Us about Patient Outcomes with Durable MCS? James K. Kirklin, MD Disclosure: I am Director of the Data Coordinating Center for the INTERMACS project and receive support through
More informationAge and Preoperative Total Bilirubin Level Can Stratify Prognosis After Extracorporeal Pulsatile Left Ventricular Assist Device Implantation
Circulation Journal Official Journal of the Japanese Circulation Society http://www.j-circ.or.jp ORIGINAL ARTICLE Cardiovascular Surgery Age and Preoperative Total Bilirubin Level Can Stratify Prognosis
More informationInitial Experience of Conversion of Toyobo Paracorporeal Left Ventricular Assist Device to DuraHeart Left Ventricular Assist Device
Circulation Journal Official Journal of the Japanese Circulation Society http://www.j-circ.or.jp Advance Publication by J-STAGE Initial Experience of Conversion of Toyobo Paracorporeal Left Ventricular
More informationRecent Trials With Durable LVADs: Is There a Superior Device?
Recent Trials With Durable LVADs: Is There a Superior Device? Francis D. Pagani MD PhD Otto Gago MD Endowed Professor of Cardiac Surgery Michigan Medicine Current Device Landscape 2018 HeartMate 3 HeartMate
More informationเอกราช อร ยะช ยพาณ ชย
30 July 2016 เอกราช อร ยะช ยพาณ ชย Heart Failure and Transplant Cardiology aekarach.a@chula.ac.th Disclosure Speaker, CME service: Merck, Otsuka, Servier Consultant, non-cme service: Novartis, Menarini
More informationPredicting Survival in Patients Receiving Continuous Flow Left Ventricular Assist Devices
Journal of the American College of Cardiology Vol. 61, No. 3, 2013 2013 by the American College of Cardiology Foundation ISSN 0735-1097/$36.00 Published by Elsevier Inc. http://dx.doi.org/10.1016/j.jacc.2012.09.055
More informationVentricular Assist Device: Are Early Interventions Superior? Hamang Patel, MD Section of Cardiomyopathy & Heart Transplantation
Ventricular Assist Device: Are Early Interventions Superior? Hamang Patel, MD Section of Cardiomyopathy & Heart Transplantation Objectives Current rationale behind use of MCS Patient Selection Earlier?
More informationBridge to Heart Transplantation
Bridge to Heart Transplantation Ulf Kjellman MD, PhD Senior Consultant Surgeon Heart Centre KFSH&RC 1 Disclosure Appointed for Proctorship by Thoratec/St.Jude/Abbott 2 To run a full overall covering transplant
More informationPediatric Mechanical Circulatory Support - What to Use
Pediatric Mechanical Circulatory Support - What to Use Ronald K. Woods, MD, PhD Associate Professor Medical College of Wisconsin Pediatric Cardiothoracic Surgery Children s Hospital of Wisconsin Disclosure
More informationPediatric Mechanical Circulatory Support (MCS)
Pediatric Mechanical Circulatory Support (MCS) Ivan Wilmot, MD Heart Failure, Transplant, MCS Assistant Professor The Heart Institute Cincinnati Children s Hospital Medical Center The University of Cincinnati
More informationEMS and Nursing Considerations in VAD Patient Care
EMS and Nursing Considerations in VAD Patient Care B R I T T A N Y B U T Z L E R B S N R N V A D C O O R D I N A T O R F R O E D T E R T A N D T H E M E D I C A L C O L L E G E O F W I 1 0 / 2 5 / 1 8
More informationDisclosures. No disclosures to report
Disclosures No disclosures to report Update on MOMENTUM 3 Trial: The Final Word? Francis D. Pagani MD PhD Otto Gago MD Professor of Cardiac Surgery University of Michigan Ann Arbor, Michigan, USA LVAD
More informationCombination Evaluation of Preoperative Risk Indices Predicts Requirement of Biventricular Assist Device
Circulation Journal Official Journal of the Japanese Circulation Society http://www.j-circ.or.jp ORIGINAL ARTICLE Heart Failure Combination Evaluation of Preoperative Risk Indices Predicts Requirement
More informationAdvances in Advanced Heart Failure Therapies. Disclosures. Management Algorithm for Patients in Cardiogenic Shock
Advances in Advanced Heart Failure Therapies 9 th Annual Dartmouth Conference on Advances in Heart Failure Therapies Dartmouth-Hitchcock Medical Center May 20, 2013 Joseph G. Rogers, M.D. Associate Professor
More informationDuraHeart TM Magnetically Levitated Left Ventricular Assist Device
1736 SAKAGUCHI T et al. Circulation Journal ORIGINAL ARTICLE Official Journal of the Japanese Circulation Society http://www.j-circ.or.jp Cardiovascular Surgery DuraHeart TM Magnetically Levitated Left
More informationImplantable Ventricular Assist Devices and Total Artificial Hearts. Policy Specific Section: June 13, 1997 March 29, 2013
Medical Policy Implantable Ventricular Assist Devices and Total Artificial Hearts Type: Medical Necessity and Investigational / Experimental Policy Specific Section: Surgery Original Policy Date: Effective
More informationMechanical Cardiac Support in Acute Heart Failure. Michael Felker, MD, MHS Associate Professor of Medicine Director of Heart Failure Research
Mechanical Cardiac Support in Acute Heart Failure Michael Felker, MD, MHS Associate Professor of Medicine Director of Heart Failure Research Disclosures Research Support and/or Consulting NHLBI Amgen Cytokinetics
More informationWhen to implant VAD in patients with heart transplantation indication. Aldo Cannata Dept of Cardiac Surgery Niguarda Ca Granda Hospital Milano
When to implant VAD in patients with heart transplantation indication Aldo Cannata Dept of Cardiac Surgery Niguarda Ca Granda Hospital Milano LVAD strategies In waiting list? Goal Bridge to transplant
More informationDo we really need an Artificial Heart? No!! John V. Conte, MD, Professor of Surgery Johns Hopkins University School of Medicine
Do we really need an Artificial Heart? No!! John V. Conte, MD, Professor of Surgery Johns Hopkins University School of Medicine Division of Cardiac Surgery The Johns Hopkins Medical Institutions Conflict
More informationPredictor of Early Mortality for Severe Heart Failure Patients With Left Ventricular Assist Device Implantation
Circulation Journal Official Journal of the Japanese Circulation Society http://www.j-circ.or.jp ORIGINAL ARTICLE Cardiovascular Surgery Predictor of Early Mortality for Severe Heart Failure Patients With
More informationVentricular Assist Device Implant in the Elderly Is Associated With Increased, but Respectable Risk: A Multi-Institutional Study
Ventricular Assist Device Implant in the Elderly Is Associated With Increased, but Respectable Risk: A Multi-Institutional Study Pavan Atluri, MD, Andrew B. Goldstone, MD, Dale M. Kobrin, BA, Jeffrey E.
More informationDiagnosis of Device Thrombosis
Diagnosis of Device Thrombosis Andrew Civitello MD, FACC Medical Director, Heart Transplant Program Director, Fellowship Co-Director, Baylor St. Luke's Medical Center / Texas Heart Institute Trends in
More informationSeventh INTERMACS annual report: 15,000 patients and counting
http://www.jhltonline.org INTERMACS ANNUAL REPORT Seventh INTERMACS annual report: 15,000 patients and counting James K. Kirklin, MD, a David C. Naftel, PhD, a Francis D. Pagani, MD, PhD, b Robert L. Kormos,
More informationPerioperative Management of the Mechanical Circulatory Support Patient. American Association of Thoracic Surgeons Allied Health Symposium May 4, 2013
Perioperative Management of the Mechanical Circulatory Support Patient American Association of Thoracic Surgeons Allied Health Symposium May 4, 2013 Disclosures None 2012 MFMER slide-2 Objectives Review
More informationA thesis submitted to the. Graduate School. of the University of Cincinnati. in partial fulfillment of the. requirements for the degree of
Virtual Implantation Of Mechanical Circulatory Support Devices A thesis submitted to the Graduate School of the University of Cincinnati in partial fulfillment of the requirements for the degree of Master
More informationDestination Therapy SO MUCH DATA IN SUCH A SMALL DEVICE. HeartWare HVAD System The ONLY intrapericardial VAD approved for DT.
DT Destination Therapy SO MUCH DATA IN SUCH A SMALL DEVICE. HeartWare HVAD System The ONLY intrapericardial VAD approved for DT. ONLY WE HAVE THIS BREADTH OF CLINICAL EVIDENCE TO SUPPORT DESTINATION THERAPY.
More informationDECLARATION OF CONFLICT OF INTEREST
DECLARATION OF CONFLICT OF INTEREST Cardiogenic Shock Mechanical Support Eulàlia Roig FESC Heart Failure and HT Unit Hospital Sant Pau - UAB Barcelona. Spain No conflics of interest Mechanical Circulatory
More informationMEDICAL POLICY SUBJECT: VENTRICULAR ASSIST DEVICES. POLICY NUMBER: CATEGORY: Technology Assessment
MEDICAL POLICY SUBJECT: VENTRICULAR ASSIST DEVICES PAGE: 1 OF: 8 If a product excludes coverage for a service, it is not covered, and medical policy criteria do not apply. If a commercial product (including
More informationNew Trends and Indications for LVADs
New Trends and Indications for LVADs Mark S. Slaughter, MD Professor and Chief Division of Thoracic and Cardiovascular Surgery University of Louisville Natural History of Heart Failure 100 10 Class III
More informationEcho in Heart Failure
Echo in Heart Failure Karima Addetia, MD Heart Failure: Definition A clinical syndrome that results from impairment of ventricular filling or ejection of blood. Manifestations include dyspnea and fatigue,
More informationVentricular Assisting Devices in the Cathlab. Unrestricted
Ventricular Assisting Devices in the Cathlab Unrestricted What is a VAD? A single system device that is surgically attached to the left ventricle of the heart and to the aorta for left ventricular support
More informationComplications in CHD with a little help from our friends
Complications in CHD with a little help from our friends Systemic ventricular failure how can the surgeon help? Assist device or transplantation? Michael Huebler (Zurich, CH) Survivors of CHD Curative
More informationLVADs as a long term or destination therapy for the advanced heart failure
LVADs as a long term or destination therapy for the advanced heart failure Prof. Davor Miličić, MD, PhD University of Zagreb School of Medicine Department of Cardiovascular Diseases University Hospital
More informationThe Balancing Act Bleeding and Thrombosis in MCS. Muhammad Adil Soofi
The Balancing Act Bleeding and Thrombosis in MCS Muhammad Adil Soofi Road Map Survival and complications with LVAD What is the Burden of thrombosis and bleeding Why Bleeding and Thrombosis happen When
More informationTotal Artificial Hearts and Implantable Ventricular Assist Devices
Total Artificial Hearts and Implantable Ventricular Assist Devices Policy Number: 7.03.11 Last Review: 12/2018 Origination: 12/2001 Next Review: 12/2019 Policy Blue Cross and Blue Shield of Kansas City
More informationAndrew Civitello MD, FACC
Timing the Transition from Short Term to Long Term Mechanical Circulatory Support Andrew Civitello MD, FACC Medical Director, Heart Transplant Program Director, Fellowship Co-Director, Baylor St. Luke's
More informationChallenges to MCS Use in the Middle East
Challenges to MCS Use in the Middle East Feras Khaliel, MD, Ph.D Consultant Cardiac Surgeon Associate Professor of Surgery, Alfaisal Univerisity King Faisal Specialist Hospital & Research Center Dr. Michael
More informationOutcomes after stroke complicating left ventricular assist device
http://www.jhltonline.org Outcomes after stroke complicating left ventricular assist device Joshua Z. Willey, MD, MS, a Michael V. Gavalas, MD, b Pauline N. Trinh, MPH, c Melana Yuzefpolskaya, MD, b A.
More informationMinimally Invasive Insertion of HVAD
Minimally Invasive Insertion of HVAD Simon Maltais, MD PhD Vice-Chair of Clinical Practice Director of MCS Program Department of Cardiovascular Surgery Mayo Clinic, Rochester, MN AATS MCS 2018, Houston
More informationExtracorporeal life support in preoperative and postoperative heart transplant management
Review Article Page 1 of 6 Extracorporeal life support in preoperative and postoperative heart transplant management Christian A. Bermudez 1, D. Michael McMullan 2 1 Division of Cardiovascular Surgery,
More informationPredicting Major Outcomes after MCSD Implant. Risk Factors for Death, Transplant, and Recovery. James Kirklin, MD David Naftel, PhD
Predicting Major Outcomes after MCSD Implant Risk Factors for Death, Transplant, and Recovery James Kirklin, MD David Naftel, PhD 1 I have no financial disclosures (I am the Principle Investigator for
More informationAllinaHealthSystem 1
: Definition End-organ hypoperfusion secondary to cardiac failure Venoarterial ECMO: Patient Selection Michael A. Samara, MD FACC Advanced Heart Failure, Cardiac Transplant & Mechanical Circulatory Support
More informationSize Limitation for Current Continuous Flow Pumps: How young can we go?
Size Limitation for Current Continuous Flow Pumps: How young can we go? Iki Adachi, M.D. Associate Surgeon Texas Children s Hospital Assistant Professor Baylor College of Medicine How young can we go?
More informationMechanical assist patient selection, device selection, and outcomes
Mechanical assist patient selection, device selection, and outcomes Josef Stehlik, MD, MPH Associate Professor of Medicine Medical Director, Heart Transplant Program University of Utah School of Medicine
More informationEffects of the HeartMate II continuous-flow left ventricular assist device on right ventricular function
http://www.jhltonline.org Effects of the HeartMate II continuous-flow left ventricular assist device on right ventricular function Sangjin Lee, MD, a Forum Kamdar, MD, a Richard Madlon-Kay, MD, a Andrew
More informationIntrapericardial Left Ventricular Assist Device for Advanced Heart Failure
The new england journal of medicine Original Article Intrapericardial Left Ventricular Assist Device for Advanced Heart Failure Joseph G. Rogers, M.D., Francis D. Pagani, M.D., Ph.D., Antone J. Tatooles,
More informationDerivation and Validation of a Novel Right-Sided Heart Failure Model After Implantation of Continuous Flow Left Ventricular Assist Devices: the EUROMACS-RHF Risk Score Osama I.I. Soliman, MD, PhD, FACC,
More informationBerlin Heart Pediatric Assistance Device: The Beginnings, The Teachings And The Cruising Speed : A Monocentric Experience With The Same System
Berlin Heart Pediatric Assistance Device: The Beginnings, The Teachings And The Cruising Speed : A Monocentric Experience With The Same System Roland Henaine, Mathieu Vergnat, Geoffray Keller, Magali Veyrier,
More informationMechanical Circulatory Support (MCS): What Every Pharmacist Needs to Know!
Mechanical Circulatory Support (MCS): What Every Pharmacist Needs to Know! Matthew A. Wanat, PharmD, BCPS, BCCCP, FCCM Clinical Assistant Professor University of Houston College of Pharmacy Clinical Pharmacy
More informationUnderstanding the Pediatric Ventricular Assist Device
Understanding the Pediatric Ventricular Assist Device W. James Parks, MSc., MD Pediatric Cardiologist Assistant Professor of Pediatrics and Radiology Children s Healthcare of Atlanta Sibley Heart Center
More informationImplantable Ventricular Assist Devices and Total Artificial Hearts
Implantable Ventricular Assist Devices and Total Artificial Hearts Policy Number: Original Effective Date: MM.06.017 05/21/1999 Line(s) of Business: Current Effective Date: PPO; HMO; QUEST Integration
More informationUpdate on Mechanical Circulatory Support. AATS May 5, 2010 Toronto, ON Canada
Update on Mechanical Circulatory Support AATS May 5, 2010 Toronto, ON Canada Disclosures NONE Emergency Circulatory Support ECMO Tandem Heart Impella Assessment Cardiac Function Pulmonary function Valvular
More informationHeart failure (HF) is a public health problem associated
Circ J doi: 10.1253/circj.CJ-18-0294 Advance Publication by-j-stage ORIGINAL ARTICLE Cardiovascular Surgery Impact of Recurrent Ventricular Tachyarrhythmia on Outcome in Japanese Heart Transplant Candidates
More informationHeartWare ventricular assist system for bridge to transplant: Combined results of the bridge to transplant and continued access protocol trial
http://www.jhltonline.org FEATURED ARTICLES HeartWare ventricular assist system for bridge to transplant: Combined results of the bridge to transplant and continued access protocol trial Mark S. Slaughter,
More informationMulticenter Evaluation of an Intrapericardial Left Ventricular Assist System
Journal of the American College of Cardiology Vol. 57, No. 12, 2011 2011 by the American College of Cardiology Foundation ISSN 0735-1097/$36.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2010.10.040
More informationReversal of secondary pulmonary hypertension by axial and pulsatile mechanical circulatory support
http://www.jhltonline.org Reversal of secondary pulmonary hypertension by axial and pulsatile mechanical circulatory support Guillermo Torre-Amione, MD, PhD, a Robert E. Southard, MD, b Matthias M. Loebe,
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Total Artificial Hearts and Ventricular Assist Devices Page 1 of 39 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Total Artificial Hearts and Ventricular Assist
More informationKnowing your treatment options can give you hope for a longer, better life
Heart failure is a deadly disease Knowing your treatment options can give you hope for a longer, better life With heart failure, it was not a matter of if I would get worse; it was a matter of when, and
More informationPerioperative Hypoalbuminemia Affects Improvement in Exercise Tolerance After Left Ventricular Assist Device Implantation
1970 IMAMURA T et al. Circulation Journal ORIGINAL ARTICLE Official Journal of the Japanese Circulation Society http://www.j-circ.or.jp Cardiovascular Surgery Perioperative Hypoalbuminemia Affects Improvement
More informationSixth INTERMACS annual report: A 10,000-patient database
http://www.jhltonline.org INTERMACS ANNUAL FEATURE Sixth INTERMACS annu report: A 10,000-patient database James K. Kirklin, MD, a David C. Naftel, PhD, a Francis D. Pagani, MD, PhD, b Robert L. Kormos,
More informationCerebral strokes in children on intracorporeal ventricular assist devices: analysis of the EUROMACS Registry
European Journal of Cardio-Thoracic Surgery 0 (2017) 1 6 doi:10.1093/ejcts/ezx342 ORIGINAL ARTICLE Cite this article as: Schweiger M, Miera O, de By TM, Hübler M, Berger F, Özbaran M et al. Cerebral strokes
More informationHow do Readmissions Impact Survival among Patients with Continuous-Flow Left Ventricular Assist Devices? Findings from INTERMACS
How do Readmissions Impact Survival among Patients with Continuous-Flow Left Ventricular Assist Devices? Findings from INTERMACS Rey P. Vivo, MD 1 ; Selim R. Krim, MD 2 ; Jerry D. Estep, MD 3 ; Wissam
More information